DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial
2023 · EClinicalMedicine · 6 citations
https://doi.org/10.1016/j.eclinm.2023.102334